Dabigatran versus enoxaparin after total hip replacement

Lancet

Volumn 370, Issue 9604, 2007, Pages 2002-2003

  Martins, Herlon S ^a   Scalabrini Neto, Augusto ^a   Velasco, Irineu T ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

DABIGATRAN; ENOXAPARIN; FONDAPARINUX; LOW MOLECULAR WEIGHT HEPARIN; ANTICOAGULANT AGENT; BENZIMIDAZOLE DERIVATIVE; DABIGATRAN ETEXILATE; PYRIDINE DERIVATIVE;

COST CONTROL; COST EFFECTIVENESS ANALYSIS; DEEP VEIN THROMBOSIS; DRUG EFFICACY; HUMAN; LETTER; MAJOR SURGERY; ORTHOPEDIC SURGERY; PHLEBOGRAPHY; PRIORITY JOURNAL; TOTAL HIP PROSTHESIS; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM; COST BENEFIT ANALYSIS; ECONOMICS; HIP ARTHROPLASTY; NOTE; POSTOPERATIVE COMPLICATION; RADIOGRAPHY;

ANTICOAGULANTS; ARTHROPLASTY, REPLACEMENT, HIP; BENZIMIDAZOLES; COST-BENEFIT ANALYSIS; ENOXAPARIN; HUMANS; PHLEBOGRAPHY; POSTOPERATIVE COMPLICATIONS; PYRIDINES; VENOUS THROMBOEMBOLISM;

EID: 36849076143     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(07)61859-5     Document Type: Letter

References (5)

1. Eriksson B., Dahl O., Rosencher N., et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet 370 (2007) 949-956
2. O'Donnell M., Linkins L., Kearon C., et al. Reduction of out-of-hospital symptomatic venous thromboembolism by extended thromboprophylaxis with low-molecular-weight heparin following elective hip arthroplasty: a systematic review. Arch Intern Med 163 (2003) 1362-1366
3. Skedgel C., Goeree R., Pleasance S., et al. The cost-effectiveness of extended-duration antithrombotic prophylaxis after total hip arthroplasty. J Bone Joint Surg Am 89 (2007) 819-828
4. Turpie A., Bauer K., Eriksson B., et al. Superiority of fondaparinux over enoxaparin in preventing venous thromboembolism in major orthopedic surgery using different efficacy end points. Chest 126 (2004) 501-508
5. Gordois A., Posnett J., Borris L., et al. The cost-effectiveness of fondaparinux compared with enoxaparin as prophylaxis against thromboembolism following major orthopedic surgery. Thromb Haemost 1 (2003) 2167-2174